The Board of Innate Immunotherapeutics Limited (ASX:IIL) (“Innate”) has resolved to make a private placement (“Placement”) to raise gross proceeds of A$2,000,000.
Innate intends to use the proceeds of the Placement for additional working capital beyond the planned release of Phase 2B trial results in the third quarter of 2017.
The Placement, which was oversubscribed, has been effected through Bell Potter Securities Limited as sole manager.
For further information please download PDF attached:
Download this document